BioSpace News Archive

IDEX Corporation announced that it has completed its previously-announced acquisition of Iridian Spectral Technologies, a global leader in designing and manufacturing thin-film, multi-layer optical filters.

Affimed N.V. announced that its 2023 Annual General Meeting of Shareholders will be held on June 21, 2023 at 14:00 CET at the NH Collection Amsterdam Barbizon Palace, Prins Hendrikkade 59-72, 1012 AD Amsterdam, the Netherlands.

Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced the appointment of Dr. Michael Croft and Dr. Jeff Edelson to the company’s Scientific Advisory Board (SAB).

Kymera Therapeutics, Inc. today announced the appointment of Jeremy Chadwick, Ph.D., as Chief Operating Officer.

Centessa Pharmaceuticals plc today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SerpinPC, an investigational novel inhibitor of activated protein C (APC) being developed for the treatment of hemophilia B, with or without inhibitors.

Milestone Pharmaceuticals Inc. today announced promising data from an ad hoc analysis of a subset of patients experiencing atrial fibrillation with rapid ventricular rate (AFib-RVR) in the NODE-303 study, which evaluated etripamil, the Company’s investigational calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT).

Endotronix, Inc. today announced positive 12-month data from the SIRONA 2 clinical trial that demonstrated long-term use of the Cordella Pulmonary Artery (PA) Sensor was associated with significant improvements in patient quality-of-life metrics and low HF hospitalization and death (HFH/D) event rates for New York Heart Failure (NYHA) class III patients.

Coya previously announced results from an open-label study of COYA 301 in 8 patients with Alzheimer’s disease (AD) that resulted in a statistically significant improvement in cognitive function, as measured by the Mini-Mental State Examination test (MMSE).

Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced it will effect a one-for-13 reverse stock split of its issued and outstanding common stock.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced planned enrollment of the PEERLESS II trial, Inari’s third randomized controlled trial (RCT) in venous thromboembolism (VTE).